Suppr超能文献

利用针对病毒刺突蛋白的抗体-金纳米粒子生物缀合物通过动态光散射检测 SARS-CoV-2 病毒。

Detection of SARS-CoV-2 virus via dynamic light scattering using antibody-gold nanoparticle bioconjugates against viral spike protein.

机构信息

Laboratory of Nanobiotechnology, Department of Genetics and Morphology, Institute of Biological Sciences, University of Brasilia, Brasilia, Distrito Federal, 70910-900, Brazil.

Virology and Microscopy Laboratory, Cell Biology Department, Institute of Biological Sciences, University of Brasilia, Brasilia, Distrito Federal, 70910-900, Brazil.

出版信息

Talanta. 2022 Jun 1;243:123355. doi: 10.1016/j.talanta.2022.123355. Epub 2022 Mar 4.

Abstract

Mass testing for the diagnosis of COVID-19 has been hampered in many countries owing to the high cost of genetic material detection. This study reports on a low-cost immunoassay for detecting SARS-CoV-2 within 30 min using dynamic light scattering (DLS). The immunosensor comprises 50-nm gold nanoparticles (AuNPs) functionalized with antibodies against SARS-CoV-2 spike glycoprotein, whose bioconjugation was confirmed using transmission electron microscopy (TEM), UV-Vis spectroscopy, Fourier transform infrared spectroscopy (FTIR), and surface-enhanced Raman scattering spectroscopy (SERS). The specific binding of the bioconjugates to the spike protein led to an increase in bioconjugate size, with a limit of detection (LOD) 5.29 × 10 TCID/mL (Tissue Culture Infectious Dose). The immunosensor was also proven to be selective upon interaction with influenza viruses once no increase in size was observed after DLS measurement. The strategy proposed here aimed to use antibodies conjugated to AuNPs as a generic platform that can be extended to other detection principles, enabling technologies for low-cost mass testing for COVID-19.

摘要

由于遗传物质检测的成本高,许多国家的 COVID-19 大规模检测受到阻碍。本研究报告了一种使用动态光散射(DLS)在 30 分钟内检测 SARS-CoV-2 的低成本免疫测定法。该免疫传感器由 50nm 金纳米粒子(AuNPs)组成,这些纳米粒子通过与 SARS-CoV-2 刺突糖蛋白的抗体结合而功能化,其生物共轭物使用透射电子显微镜(TEM)、紫外-可见光谱、傅里叶变换红外光谱(FTIR)和表面增强拉曼散射光谱(SERS)进行了确认。生物共轭物与刺突蛋白的特异性结合导致生物共轭物尺寸增加,检测限(LOD)为 5.29×10 TCID/mL(组织培养感染剂量)。通过 DLS 测量后观察到尺寸没有增加,证明免疫传感器与流感病毒相互作用时具有选择性。这里提出的策略旨在使用与 AuNPs 共轭的抗体作为通用平台,该平台可以扩展到其他检测原理,从而实现 COVID-19 的低成本大规模检测技术。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c241/8895652/4ced4c8fc4d4/ga1_lrg.jpg

相似文献

引用本文的文献

本文引用的文献

2
A Review of COVID-19 Mass Testing in the United Arab Emirates.阿联酋的 COVID-19 大规模检测回顾。
Front Public Health. 2021 May 12;9:661134. doi: 10.3389/fpubh.2021.661134. eCollection 2021.
3
CRISPR-Based COVID-19 Testing: Toward Next-Generation Point-of-Care Diagnostics.基于 CRISPR 的 COVID-19 检测:迈向新一代即时诊断。
Front Cell Infect Microbiol. 2021 Apr 30;11:663949. doi: 10.3389/fcimb.2021.663949. eCollection 2021.
5
Mass testing for COVID-19.新冠病毒大规模检测。
Lancet Microbe. 2020 Dec;1(8):e317. doi: 10.1016/S2666-5247(20)30205-6. Epub 2020 Dec 7.
6
Evolution of antibody immunity to SARS-CoV-2.SARS-CoV-2 抗体免疫的演变。
Nature. 2021 Mar;591(7851):639-644. doi: 10.1038/s41586-021-03207-w. Epub 2021 Jan 18.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验